Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

BACKGROUND: Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma. METHODS: Patients had ECOG performance status 0–2 and normal organ function. Dacarbazine was administered on day 1 and da...

Descripción completa

Detalles Bibliográficos
Autores principales: Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251861/
https://www.ncbi.nlm.nih.gov/pubmed/22127285
http://dx.doi.org/10.1038/bjc.2011.514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251861/
https://www.ncbi.nlm.nih.gov/pubmed/22127285
http://dx.doi.org/10.1038/bjc.2011.514

Ejemplares similares